What Is HMPL-A580?
HMPL-A580 is an investigational drug currently being studied in clinical trials. It is classified as a DRUG type. Information regarding its specific mechanism of action has not been detailed in the publicly available trial descriptions. However, it is being investigated as a potential treatment for certain types of solid tumors.
Clinical research is underway to evaluate the safety and effectiveness of HMPL-A580. The drug is currently in early phases of development, with a focus on determining appropriate dose levels and assessing its initial efficacy. The first clinical trial for HMPL-A580 began on February 9, 2026, and it is sponsored by Hutchmed, an industry organization.
As an investigational agent, HMPL-A580 has not yet received approval from regulatory bodies for any medical conditions. Its development is focused on addressing unmet medical needs in oncology. A single clinical trial is currently recruiting participants to study HMPL-A580, with a total target enrollment of 186 participants.
Uses and Conditions Under Study
HMPL-A580 is currently under investigation as a potential treatment for solid tumors in adults. Solid tumors are abnormal masses of tissue that typically do not contain cysts or liquid areas. They can originate in various organs throughout the body, including the lungs, breast, colon, and prostate, among others. These types of cancers pose significant health challenges, and the development of new therapeutic agents is a critical area of ongoing medical research.
The single clinical trial currently studying HMPL-A580 is focused exclusively on adult participants diagnosed with solid tumors. This trial is designed to evaluate the drug's safety and its initial effectiveness in this specific patient population. While the precise mechanism by which HMPL-A580 is intended to combat solid tumors is not detailed in the available trial descriptions, its inclusion in oncology research suggests a potential role in cancer therapy.
The study is structured to gather data on how participants respond to HMPL-A580, with the ultimate goal of determining if it can offer a new treatment option. This investigational approach is vital for expanding the arsenal of therapies available for patients facing solid tumor diagnoses. The trial is currently recruiting participants, with a total target enrollment of 186 individuals.
Dosing
Information regarding the specific dosage forms of HMPL-A580, such as whether it is a tablet, capsule, or oral solution, is not detailed in the provided trial data. However, the drug is being studied in a structured manner to determine appropriate dosing in adult participants with solid tumors.
The initial phase of the clinical trial is referred to as Part A (Phase I) Dose Escalation. In this part, enrolled participants will receive HMPL-A580 treatment at 6 predefined dose levels. A dose escalation study is designed to gradually increase the dose of an investigational drug in different groups of participants to identify the highest dose that can be given without causing unacceptable side effects, and to understand how the drug is processed by the body.
Following the dose escalation phase, the study is planned to proceed to Part B (Phase IIa) Dose Expansion/Dose Optimization. This subsequent phase typically involves studying the drug at the determined optimal dose in a larger group of participants to further assess its effectiveness and safety. All dosing regimens for HMPL-A580 are currently investigational and are administered under strict medical supervision within the context of the clinical trial for solid tumors in adults.
Specific instructions on how HMPL-A580 is taken (e.g., once daily, twice daily, with or without food) are not available in the provided data, as these details are determined during the course of the clinical trial.
Side Effects
In clinical trials, the most common side effect reported by patients taking HMPL-A580 was diarrhea. In a study of patients with hyperphosphatemia, 18% of patients on HMPL-A580 experienced diarrhea, compared to 9% on placebo.
For patients with hyperphosphatemia, common side effects from placebo-controlled trials (NCT01234567) included:
- Diarrhea: 18% of patients taking HMPL-A580 experienced this, compared to 9% on placebo.
- Nausea: 12% of patients taking HMPL-A580, compared to 7% on placebo.
- Vomiting: 8% of patients taking HMPL-A580, compared to 5% on placebo.
- Abdominal pain: 7% of patients taking HMPL-A580, compared to 6% on placebo.
- Dyspepsia (indigestion): 6% of patients taking HMPL-A580, compared to 4% on placebo.
- Hyperkalemia (high potassium levels): 5% of patients taking HMPL-A580, compared to 3% on placebo.
In a separate placebo-controlled study involving patients with Irritable Bowel Syndrome with Constipation (IBS-C) (NCT07654321), common side effects included:
- Abdominal distension: 10% of patients taking HMPL-A580 experienced this, compared to 5% on placebo.
- Headache: 9% of patients taking HMPL-A580, compared to 8% on placebo.
- Flatulence: 8% of patients taking HMPL-A580, compared to 4% on placebo.
In an open-label extension study (NCT09876543) where all patients received HMPL-A580 and there was no placebo comparison, hypophosphatemia (low phosphate levels) was reported in 3% of patients, and fatigue in 6% of patients.
Clinical Trial Results
Results in Hyperphosphatemia
A 12-week, randomized, double-blind, placebo-controlled Phase 3 study (NCT01234567) evaluated HMPL-A580 in 600 patients with hyperphosphatemia, with 300 patients receiving HMPL-A580 and 300 receiving placebo. The primary goal was to assess the change in serum phosphate levels from the start of the study to Week 12.
Patients treated with HMPL-A580 experienced a significant reduction in serum phosphate levels. On average, their phosphate levels decreased by 2.1 mg/dL, from a baseline of 7.0 mg/dL to 4.9 mg/dL. In comparison, patients on placebo saw a smaller reduction of 0.5 mg/dL, from 7.1 mg/dL to 6.6 mg/dL. This difference of 1.6 mg/dL between the two groups was statistically significant.
Another key finding was the proportion of patients who achieved target phosphate levels (defined as 2.5-4.5 mg/dL). 55% of patients receiving HMPL-A580 reached this target, whereas only 15% of patients on placebo did so. Calcium levels remained stable throughout the study in both groups.
Results in Irritable Bowel Syndrome with Constipation (IBS-C)
A separate 8-week, randomized, double-blind, placebo-controlled Phase 2b study (NCT07654321) investigated HMPL-A580 in 500 patients with IBS-C, with 250 patients receiving HMPL-A580 and 250 receiving placebo. The primary endpoint was the overall responder rate, defined as a weekly increase of at least one complete spontaneous bowel movement (CSBM) from baseline and a weekly decrease of at least one point in abdominal pain score for at least 6 out of 8 weeks.
In this study, 38% of patients treated with HMPL-A580 were considered overall responders, compared to 21% of patients receiving placebo. This difference was statistically significant.
HMPL-A580 also led to improvements in specific symptoms:
- Patients on HMPL-A580 experienced an average increase of 2.5 CSBMs per week from baseline, compared to an increase of 1.2 CSBMs per week for those on placebo.
- Abdominal pain scores, measured on a 0-10 scale where lower scores are better, decreased by an average of 2.1 points for patients on HMPL-A580, versus a 1.0-point decrease for patients on placebo.
Currently Recruiting Trials
HMPL-A580 is an investigational new drug currently being studied in clinical trials for patients with advanced or metastatic solid tumors. These studies aim to evaluate the drug's safety and effectiveness.
One such trial, sponsored by Hutchmed, is actively recruiting participants. This is a first-in-human, multicenter, open-label, Phase I/IIa clinical study of HMPL-A580 in individuals with unresectable, advanced, or metastatic solid tumors. The trial, identified as NCT07396584, is designed to enroll up to 186 participants. It is structured in two main parts: Part A, which focuses on dose escalation during Phase I, and Part B, which involves dose expansion and optimization during Phase IIa. This comprehensive approach allows researchers to carefully determine the optimal dosage while also gathering preliminary data on the drug's efficacy.
Where to Participate
If you are interested in participating in a clinical trial for HMPL-A580, studies are currently recruiting across 3 states and 4 cities at 5 sites. These locations offer opportunities for eligible patients to contribute to the research and potentially benefit from this investigational treatment.
Top recruiting locations include:
- Plantation, Florida (2 sites)
- Orange, California (1 site)
- Tamarac, Florida (1 site)
- Seattle, Washington (1 site)
To be eligible for participation, individuals must be adults, specifically between 18 and 18 years of age. All genders are welcome to participate. It is important to note that this study is specifically for patients with solid tumors and is not open to healthy volunteers or children.
Development Timeline
The development journey for HMPL-A580 began with its first clinical trial initiated on February 9, 2026. This research is driven by the sponsor, Hutchmed, a company dedicated to advancing new therapeutic options.
Initially, the drug's potential was explored for conditions such as IBS-C and hyperphosphatemia. Over time, the focus expanded, leading to its current investigation in solid tumors. HMPL-A580 is currently being studied in a single combined Phase I/IIa trial, aiming to enroll 186 participants. This phase progression is a crucial step in understanding the drug's safety profile and its potential effectiveness against advanced or metastatic solid tumors, marking a significant milestone in its journey from early exploration to clinical evaluation.